{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T10:03:25Z","timestamp":1779617005580,"version":"3.53.1"},"reference-count":20,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ard.2025.08.022","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T11:32:49Z","timestamp":1759231969000},"page":"e73-e75","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Response to correspondence on \u2018Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: real-world data from the BIOBADASER registry\u2019 by Hern\u00e1ndez-Cruz et al."],"prefix":"10.1016","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6423-3610","authenticated-orcid":false,"given":"Blanca","family":"Hern\u00e1ndez-Cruz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ard.2025.08.022_bib0001","doi-asserted-by":"crossref","unstructured":"Correspondence on \u201cJanus Kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: real world data from the BIOBADASER registry. Pending of cite. https:\/\/doi.org\/10.1136\/ard-2023-225271.","DOI":"10.1136\/ard-2023-225271"},{"key":"10.1016\/j.ard.2025.08.022_bib0002","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.2147\/PPA.S165101","article-title":"Medication adherence and persistence in patients with autoimmune rheumatic diseases: a narrative review","volume":"12","author":"Anghel","year":"2018","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.ard.2025.08.022_bib0003","first-page":"882","article-title":"Adherence and persistence in patients with rheumatoid arthritis at an integrated health system specialty pharmacy","volume":"27","author":"Peter","year":"2021","journal-title":"J Manag Care Spec Pharm"},{"issue":"1","key":"10.1016\/j.ard.2025.08.022_bib0004","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2017-000585","article-title":"Predicting adherence to therapy in rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis: a large cross-sectional study","volume":"5","author":"Smolen","year":"2019","journal-title":"RMD Open"},{"key":"#cr-split#-10.1016\/j.ard.2025.08.022_bib0005.1","unstructured":"Ministerio De Sanidad. Sistema Nacional de Salud [Internet]. [updated 2025 Jan 14"},{"key":"#cr-split#-10.1016\/j.ard.2025.08.022_bib0005.2","unstructured":"cited 2025 Jul 19]. Available from: https:\/\/www.sanidad.gob.es\/organizacion\/sns\/home.htm."},{"key":"10.1016\/j.ard.2025.08.022_bib0006","unstructured":"VV.AA. Monograf\u00edas de Farmacia Hospitalaria y de Atenci\u00f3n Primaria. Cambio de paradigma: de la participaci\u00f3n a la validaci\u00f3n (n\u00ba 14). Barcelona Bayer Hispania SL, 2020. pp 20-39 [updated 2020 Nov 1; cited 2025 jul 19]."},{"key":"10.1016\/j.ard.2025.08.022_bib0007","first-page":"210","article-title":"Registro de acontecimientos adversos de terapias biol\u00f3gicas en enfermedades Reum\u00e1ticas: BIOBADASER","volume":"31","author":"Carmona","year":"2004","journal-title":"Rev Esp Reumatol"},{"key":"10.1016\/j.ard.2025.08.022_bib0008","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S1699-258X(05)72722-4","volume":"1","author":"Carmona","year":"2005","journal-title":"Reumatol Clin"},{"key":"#cr-split#-10.1016\/j.ard.2025.08.022_bib0009.1","unstructured":"Biobadaser 3.0. Registro Espa\u00f1ol De Acontecimientos Adversos De Terapias Biol\u00f3gicas Y Biosimilares En Enfermedades Reum\u00e1ticas [Internet]. [updated 2015 Oct 15"},{"key":"#cr-split#-10.1016\/j.ard.2025.08.022_bib0009.2","unstructured":"cited 2025 Jul 19]. Available from: https:\/\/biobadaser.ser.es\/docs\/ProtocoloBIOBADASER_V8_VersionFinal.pdf."},{"key":"10.1016\/j.ard.2025.08.022_bib0010","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.reuma.2017.08.001","article-title":"Objectives and methodology of BIOBADASER phase III","volume":"15","author":"Sanchez-Piedra","year":"2019","journal-title":"Reumatol Clin (Engl Ed)"},{"key":"10.1016\/j.ard.2025.08.022_bib0011","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2147\/PPA.S291983","article-title":"Adherence to treatment in patients with rheumatoid arthritis from Spain","volume":"15","author":"Pombo-Suarez","year":"2021","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.ard.2025.08.022_bib0012","first-page":"423","article-title":"Non-adherence to subcutaneous biological medication in patients with rheumatoid arthritis: a multicentre, non-interventional study","volume":"35","author":"Calvo-Al\u00e9n","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.ard.2025.08.022_bib0013","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.semerg.2020.06.024","volume":"47","author":"N\u00fa\u00f1ez-Rodr\u00edguez","year":"2021","journal-title":"Semergen"},{"key":"10.1016\/j.ard.2025.08.022_bib0014","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/jdv.15179","article-title":"ALIGNed on adherence: subanalysis of adherence in immune-mediated inflammatory diseases in the DACH region of the global ALIGN study","volume":"33","author":"Kolios","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ard.2025.08.022_bib0015","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1136\/ard.2009.123919","article-title":"Treating rheumatoid arthritis to target: recommendations of an international task force","volume":"69","author":"Smolen","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.08.022_bib0016","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.08.022_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2022.101742","article-title":"Precision medicine in rheumatoid arthritis","volume":"36","author":"Bhamidipati","year":"2022","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.ard.2025.08.022_bib0018","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1080\/1744666X.2019.1706484","article-title":"Is precision medicine possible in rheumatic diseases? Lessons from selective use of targeted therapies in patients with psoriatic arthritis","volume":"16","author":"Miyagawa","year":"2020","journal-title":"Expert Rev Clin Immunol"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496725043225?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496725043225?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T09:18:24Z","timestamp":1779614304000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496725043225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":20,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S0003496725043225"],"URL":"https:\/\/doi.org\/10.1016\/j.ard.2025.08.022","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Response to correspondence on \u2018Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: real-world data from the BIOBADASER registry\u2019 by Hern\u00e1ndez-Cruz et al.","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ard.2025.08.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Alliance of Associations for Rheumatology (EULAR). Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}